High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine Behind Non Hodgkin Lymphoma (NHL) Market Evolution in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025?
The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%. This notable growth during the historical period can be ascribed to a rise in NHL cases, progresses in diagnostics, chemotherapy, and immunotherapy, as well as advancements in clinical research, drug development, and better survival rates.

How Will the Non Hodgkin Lymphoma (NHL) Market Size Evolve and Grow by 2029?
There is an expectation of robust growth in the market size of non hodgkin lymphoma (NHL) in the coming years. The predictions show that it will expand to "$15.42 billion in 2029 with a compound annual growth rate (CAGR) of 8.8%. The predicted growth in this period can be tied to the increasing senior population, advancements in targeted treatments, innovations in immunotherapy, the application of precision medicine methods, augmented awareness and prompt diagnosis. The main trends during the forecast period are the uprising of biosimilars, the integration of next-generation sequencing, the embrace of car-t cell therapies, new chemotherapy drugs, real-world evidence and outcomes studies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

What Drivers Are Propelling the Growth of Non Hodgkin Lymphoma (NHL) Market Forward?
The non-Hodgkin lymphoma market is projected to expand due to the high incidence of this condition. This particular type of cancer originates in the lymphatic system, a vital component of the immune system. The incidence of non-Hodgkin lymphoma is a measure of how many individuals at any given moment have been diagnosed or are living with this condition. Treatment for non-Hodgkin lymphoma is crucial for improving the prognosis for those who have already been diagnosed, as it focuses on controlling the cancer cells. For example, the American Cancer Society, a US-based cancer health organization, reported in January 2023 that non-Hodgkin lymphoma makes up 4% of all diagnosed cancers. It's predicted to impact approximately 80,550 Americans in 2023, including 44,880 men and 35,670 women. They also predict that about 20,180 individuals will lose their life to non-Hodgkin lymphoma in 2023. Furthermore, the Canadian Cancer Society, a national cancer charity in Canada, stated in May 2022 that 11,400 Canadians would be diagnosed with non-Hodgkin lymphoma in 2022, with 3,000 of those expected to die from the disease. Hence, the vast incidence of non-Hodgkin lymphoma is fuelling the growth of the market for this condition.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

Which Emerging Trends Are Transforming the Non Hodgkin Lymphoma (NHL) Market in 2025?
Drug development continues to drive progress in the non-Hodgkin lymphoma market. In December 2022, US-based Genentech Inc. received FDA approval for Lunsumio, a bispecific antibody used to treat relapsed or refractory follicular lymphoma. This off-the-shelf immunotherapy is available without delay and demonstrated positive Phase II results in high-risk patients.

What Are the Key Segments in the Non Hodgkin Lymphoma (NHL) Market?
The non hodgkin lymphoma (NHL) market covered in this report is segmented -

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma
2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:
1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma
2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

Who Are the Key Players Shaping the Non Hodgkin Lymphoma (NHL) Market's Competitive Landscape?
Major companies operating in the non hodgkin lymphoma (NHL) market include Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

What Geographic Markets Are Powering Growth in the Non Hodgkin Lymphoma (NHL) Market?
North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non-Hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10676

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.